A Phase 2 interventional study of Vitamin D3 and Placebo in Warts, sponsored by Stephen P. Merry. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-30.
Sponsored by Stephen P. Merry · Phase 2, Interventional, and Treatment
Among 59 studies in Warts with a site in United States — 7 open to participants now, 10 under way, 4 of them phase 3. Warts · United States.
Among the 59 studies in Warts with a site in United States, this one is the 30th largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2020, is one of 23 in phase 2, and was the 43rd registered.
171 studies on the registry are indexed under Warts; 35 are open to participants now.
Browse Warts studies →7 of the 59 studies in Warts with a site in United States are open now. Recruiting first, the newest first:
Verrica Pharmaceuticals Inc. · Sites in United States, Japan
Ages 2+
Verrica Pharmaceuticals Inc. · Sites in United States, Japan
Ages 2+
The Skin Center Dermatology Group · Sites in United States
Ages 8–18
Western Institute for Veterans Research · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Warts studies recruiting now, 10 (56%) set no upper age limit and 8 (44%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 29 · Phase 3 13 · Phase 4 5
First in 2004; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is close to the median of 70 across 155 interventional studies indexed under Warts.
Median enrollment 80 across the 58 interventional studies, 950 across the 1 observational. Of the 44 that completed or were terminated, 27 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 59 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Stephen P. Merry as lead sponsor.
Stephen P. Merry has 1 study filed under Warts — fewer than ten, so there is no comparison to draw.
5 of the studies in Warts with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07246590Phase 3Verrica Pharmaceuticals Inc.Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | 2026-11 |
| NCT07637734Phase 3Verrica Pharmaceuticals Inc.Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) | 2027-05 |
| NCT07457918Phase 3Verrica Pharmaceuticals Inc.Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) | 2027-11 |
| NCT07881952Verrica Pharmaceuticals Inc.Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5) | 2027-04 |
| NCT07806617Rush University Medical CenterIntralesional Gardasil-9 for the Treatment of Recalcitrant Warts | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 59 studies in Warts with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers are trying to find out if injecting Vitamin D into a wart is an effective treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive a Vitamin D3 injection into their wart
Drug: Vitamin D3
Subjects will receive a placebo injection into their wart
Drug: Placebo
Intralesional injection of 0.3 ml 40,000 IU/ml vitamin D3 into one wart
Also known as: Cholecalciferol
0.3 ml injection of sterilized sesame oil with no active study ingredient
Complete Regression of Wart
Number of subjects to have a complete resolution of cutaneous wart
Time frame: 24 weeks
Regression of Wart at 4 Weeks
Number of participants who experienced complete regression of cutaneous wart at 4 weeks.
Time frame: 4 weeks
Regression of Wart at 8 Weeks
Number of participants who experienced complete regression of cutaneous wart at 8 weeks.
Time frame: 8 weeks
Regression of Wart at 12 Weeks
Number of participants who experienced complete regression of cutaneous wart at 12 weeks.
Time frame: 12 weeks
| Milestone | Vitamin D3 Treatment Group | Placebo Group |
|---|---|---|
| Started | 41 | 36 |
| Completed | 41 | 36 |
| Not completed | 0 | 0 |
Number of subjects to have a complete resolution of cutaneous wart
| Participants | Vitamin D3 Treatment Group | Placebo Group |
|---|---|---|
| Complete Regression of Wart | 12 | 10 |
Number of participants who experienced complete regression of cutaneous wart at 4 weeks.
| Participants | Vitamin D3 Treatment Group | Placebo Group |
|---|---|---|
| Regression of Wart at 4 Weeks | 2 | 2 |
Number of participants who experienced complete regression of cutaneous wart at 8 weeks.
| Participants | Vitamin D3 Treatment Group | Placebo Group |
|---|---|---|
| Regression of Wart at 8 Weeks | 4 | 7 |
Number of participants who experienced complete regression of cutaneous wart at 12 weeks.
| Participants | Vitamin D3 Treatment Group | Placebo Group |
|---|---|---|
| Regression of Wart at 12 Weeks | 7 | 8 |
Collected over Adverse events were collected for each subject from the time of first injection of the investigational product until 112 days following the last administration of the investigational product, for a total of approximately 6 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vitamin D3 Treatment Group | 0/41 (0%) | 0/41 (0%) | 41/41 (100%) |
| Placebo Group | 0/36 (0%) | 0/36 (0%) | 36/36 (100%) |
| Event | Vitamin D3 Treatment Group | Placebo Group |
|---|---|---|
| ItchingGeneral disorders | 19/41 | 19/36 |
| Skin redness at injection siteGeneral disorders | 15/41 | 15/36 |
| Hematoma (blood blister)General disorders | 7/41 | 2/36 |
| Age, Continuous(years) | Vitamin D3 Treatment Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 36.7 ± 11.0 | 33.6 ± 10.1 | 35.3 ± 10.6 |
| Sex: Female, Male(Participants) | Vitamin D3 Treatment Group | Placebo Group | Total |
|---|---|---|---|
| Female | 32 | 26 | 58 |
| Male | 9 | 10 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Vitamin D3 Treatment Group | Placebo Group | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 41 | 34 | 75 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Vitamin D3 Treatment Group | Placebo Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 41 | 36 | 77 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Vitamin D3 Treatment Group | Placebo Group | Total |
|---|---|---|---|
| United States | 41 | 36 | 77 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2020 to primary completion in Apr 2023, 29 months.
Results were first posted in Apr 2024, 1 year after primary completion.
Of 18 phase 2 interventional studies under Warts, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 29 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cholecalciferol